다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Jornal brasileiro de pneumologia : publicaçao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, v.46 no.2, 2020년, pp.e20200193 -
Sgalla, Giacomo (. UOC Pneumologia, Dipartimento Scienze Gastroenterologiche, Endocrino-Metaboliche e Nefro-Urologiche, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Roma, Italia.) , Richeldi, Luca (. UOC Pneumologia, Dipartimento Scienze Gastroenterologiche, Endocrino-Metaboliche e Nefro-Urologiche, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Roma, Italia.)
초록이 없습니다.
1 Richeldi L du Bois RM Raghu G Azuma A Brown KK Costabel U Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis [published correction appears in N Engl J Med 2015 373 8 782 782 10.1056/NEJMoa1402584
2 King TE Jr Bradford WZ Castro-Bernardini S Fagan EA Glaspole I Glassberg MK A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis [published correction appears in N Engl J Med 2014 371 12 1172 1172 10.1056/NEJMoa1402582
3 Raghu G Rochwerg B Zhang Y Garcia CA Azuma A Behr J An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline [published correction appears in Am J Respir Crit Care Med 2015 192 5 644 644 10.1164/rccm.1925erratum
4 Baddini-Martinez J Ferreira J Tanni S Alves LR Cabral BF Junior Carvalho CRR Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis Official document of the Brazilian Thoracic Association based on the GRADE methodology J Bras Pneumol 2020 46 2 e20190423 10.36416/1806-3756/e20190423 32130337
5 Kolb M Raghu G Wells AU Behr J Richeldi L Schinzel B Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis N Engl J Med 2018 379 18 1722 1731 10.1056/NEJMoa1811737 30220235
6 Tran T Suissa S The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis a methodological review of observational studies Eur Respir J 2018 51 6 1800376 1800376 10.1183/13993003.00376-2018 29724921
7 Flaherty KR Wells AU Cottin V Devaraj A Walsh SLF Inoue Y Nintedanib in Progressive Fibrosing Interstitial Lung Diseases N Engl J Med 2019 381 18 1718 1727 10.1056/NEJMoa1908681 31566307
8 Maher TM Corte TJ Fischer A Kreuter M Lederer DJ Molina-Molina M Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease a double-blind, randomised, placebo-controlled, phase 2 trial Lancet Respir Med 2020 8 2 147 157 10.1016/S2213-2600(19)30341-8 31578169
9 Distler O Highland KB Gahlemann M Azuma A Fischer A Mayes MD Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease N Engl J Med 2019 380 26 2518 2528 10.1056/NEJMoa1903076 31112379
10 Raghu G van den Blink B Hamblin MJ Brown AW Golden JA Ho LA Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis A Randomized Clinical Trial JAMA 2018 319 22 2299 2307 10.1001/jama.2018.6129 29800034
11 Richeldi L Fernandez Perez ER Costabel U Albera C Lederer DJ Flaherty KR Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE) a phase 2, randomised, double-blind, placebo-controlled trial Lancet Respir Med 2020 8 1 25 33 10.1016/S2213-2600(19)30262-0 31575509
12 Maher TM van der Aar EM Van de Steen O Allamassey L Desrivot J Dupont S Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA) a phase 2a randomised placebo-controlled trial Lancet Respir Med 2018 6 8 627 635 10.1016/S2213-2600(18)30181-4 29792287
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.